Ascendis Pharma A/S (ASND) Financials: History & Chart

Ascendis Pharma A/S(ASND)

Biotechnology · Hellerup, CR

$228.03+0.16 (+0.07%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Hellerup, CR

1,189 employees

ascendispharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jan Moller Mikkelsen

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.22B	393.94M	289.59M	287.98M	250.67M	186.28M	109.18M	180.09M	64.39M
Cost of Goods Sold	120.05M	36.89M	24.98M	31.95M	26.23M	37.07M	18.94M	14.52M	12.47M
Gross Profit	1.10B	357.05M	264.60M	256.04M	224.44M	149.22M	90.23M	165.57M	51.92M
Gross Profit Margin	90.2%	90.6%	91.4%	88.9%	89.5%	80.1%	82.6%	91.9%	80.6%
Total Operating Expenses	976.13M	284.60M	235.47M	244.52M	211.54M	211.63M	202.94M	165.17M	159.64M
Research & Development	318.39M	85.27M	66.58M	88.07M	78.47M	84.85M	93.66M	82.11M	81.89M
Selling, General & Administrative	655.73M	199.33M	168.89M	156.46M	131.05M	124.60M	103.44M	81.58M	75.86M
Operating Income (EBIT)	126.01M	72.45M	29.14M	11.51M	12.90M	-62.41M	-112.70M	397K	-107.72M
Operating Margin	10.3%	18.4%	10.1%	4.0%	5.1%	-33.5%	-103.2%	0.2%	-167.3%
Income Before Tax (EBT)	112.19M	267.16M	-56.58M	-31.07M	-67.32M	-41.26M	-101.19M	-38.71M	-109.32M
Interest Income	60.37M	23.18M	5.30M	27.99M	3.90M	64.90M	31.20M	-68.91M	31.49M
Interest Expense	190.69M	16.46M	78.98M	72.12M	23.14M	38.92M	48.43M	-58.64M	28.22M
Other Income/Expense	-13.81M	194.71M	-85.71M	-42.59M	-80.22M	21.15M	11.51M	-39.11M	-1.60M
Net Income	868.74M	240.31M	739.04M	-39.05M	-71.56M	-45.80M	-102.34M	-39.83M	-110.45M
Income Tax Expense	-756.55M	26.85M	-795.62M	7.98M	4.24M	4.54M	1.15M	1.12M	1.14M
Net Profit Margin	71.1%	61.0%	255.2%	-13.6%	-28.5%	-24.6%	-93.7%	-22.1%	-171.5%
EBITDA	146.59M	77.75M	34.09M	17.13M	17.62M	-57.33M	-107.79M	5.03M	-105.82M
EBITDA Margin	12.0%	19.7%	11.8%	5.9%	7.0%	-30.8%	-98.7%	2.8%	-164.3%
Depreciation & Amortization	20.59M	5.31M	4.96M	5.61M	4.72M	5.08M	4.92M	4.63M	1.90M
EPS Basic	13.91	3.73	11.98	-0.63	-1.17	-0.75	-1.71	-0.66	-1.88
EPS Diluted	13.16	3.52	11.45	-0.63	-1.17	N/A	-1.71	-0.66	-1.88
Weighted Average Basic Shares	64.34M	64.34M	61.68M	61.38M	60.99M	60.45M	60.02M	59.79M	58.57M
Weighted Average Diluted Shares	68.32M	68.32M	64.52M	61.38M	60.99M	63.91M	60.02M	59.79M	58.57M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	812.48M	376.55M	294.39M	54.75M	8.85M	8.49M	15.01M	12.11M
Cost of Goods Sold	121.19M	45.83M	49.00M	12.99M	4.01M	0.00	0.00	0.00
Gross Profit	691.28M	330.72M	245.39M	41.77M	4.84M	8.49M	15.01M	12.11M
Gross Profit Margin	85.1%	87.8%	83.4%	76.3%	54.7%	100.0%	100.0%	100.0%
Total Operating Expenses	845.03M	619.37M	748.19M	642.87M	519.14M	412.37M	269.44M	189.23M
Research & Development	333.00M	317.90M	456.35M	406.17M	336.80M	318.71M	215.04M	160.55M
Selling, General & Administrative	512.03M	294.64M	285.64M	230.95M	182.34M	93.66M	54.40M	28.68M
Operating Income (EBIT)	-153.75M	-288.66M	-502.80M	-601.11M	-514.30M	-403.88M	-254.43M	-177.12M
Operating Margin	-18.9%	-76.7%	-170.8%	-1097.9%	-5808.6%	-4755.1%	-1695.1%	-1462.6%
Income Before Tax (EBT)	-239.92M	-386.49M	-523.34M	-618.23M	-437.06M	-512.05M	-244.93M	-149.34M
Interest Income	17.26M	14.87M	18.61M	7.95M	788K	2.21M	11.29M	4.60M
Interest Expense	90.99M	67.83M	48.64M	32.83M	4.45M	2.34M	1.37M	145K
Other Income/Expense	-86.17M	-97.83M	-20.53M	-17.12M	77.23M	-108.17M	9.50M	27.77M
Net Income	-257.28M	-391.50M	-531.40M	-623.98M	-436.64M	-511.78M	-244.66M	-148.89M
Income Tax Expense	17.36M	5.01M	8.06M	5.75M	-418K	-268K	-263K	-451K
Net Profit Margin	-31.7%	-104.0%	-180.5%	-1139.6%	-4931.6%	-6025.5%	-1630.0%	-1229.5%
EBITDA	-133.78M	-270.31M	-481.93M	-582.37M	-496.78M	-392.33M	-246.95M	-176.08M
EBITDA Margin	-16.5%	-71.8%	-163.7%	-1063.6%	-5610.7%	-4619.2%	-1645.2%	-1454.0%
Depreciation & Amortization	19.97M	18.34M	20.87M	18.74M	17.52M	11.54M	7.48M	1.04M
EPS Basic	-4.25	-6.76	-9.44	-11.13	-7.97	-10.11	-5.26	-3.63
EPS Diluted	-4.25	-6.76	-9.44	-11.13	-7.97	-10.11	-5.26	-3.63
Weighted Average Basic Shares	60.61M	57.89M	56.29M	56.07M	54.77M	50.62M	46.51M	41.09M
Weighted Average Diluted Shares	60.61M	57.89M	56.29M	56.07M	54.77M	50.62M	46.51M	41.09M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.